Merestinib, is an inhibitor of c-Met, TEK, ROS1, and TRK1/2/3 being investigated in several phase II trials for advanced biliary tract cancer, NSCLC, and other various solid tumors. This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.